Home > News & Events > Rhenovia at BIO to present its neuronal biosimulation platforms and proof of concept by RHEDAR, a new drug candidate to treat Huntington’s Disease
2 June 2012 - Rhenovia at BIO to present its neuronal biosimulation platforms and proof of concept by RHEDAR, a new drug candidate to treat Huntington’s Disease
Mulhouse, France, Cambridge, MA and Los Angeles, CA June 4th, 2012
Rhenovia Pharma and Rhenovia Inc. represented by Serge Bischoff, President and CEO, Jean-Marie Bouteiller, Director of Biosimulation Platforms and Bernard Malfroy-Camine, Business Development Advisor are pleased to meet with you at the BIO International Convention in Boston (June 17-21, 2012).
This will be a great opportunity for us to present the recent developments of Rhenovia highlighted by the creation, in January 2012 of Rhenovia Inc., the first subsidiary of Rhenovia Pharma, incorporated in Delaware and having started its operations in the Greater Boston (MA) and Los Angeles (CA) areas. With this creation, Rhenovia is aiming at getting closer to its partners in North America, providing services based on our biosimulation platforms and offering for out-licensing our flagship compound RHEDAR.
We would be glad to provide you with information on the progress made with our platforms, the expansion from a hippocampus towards a striatum platform, the therapeutic applications for cognitive deficit, epilepsy, stroke, Huntington's disease, and more generally diseases linked the glutamate/GABA imbalance, calcium deregulation and channelopathies. The various programs we have presently running including mGluRs, nicotinic cholinergic, NMDA and AMPA receptor modulators, dopamine-glutamate-acetylcholine and GABA interactions, second messenger cascades as well as a more recent launch of specific programs in rare diseases such as Huntington's disease and Duchenne muscular dystrophies (DMD) offer highly efficient tools to boost the search for new treatments to pharma and biotech companies as well as to optimize the more basic research to academic institutions, patient foundations and government organizations.
With Jean-Marie and Bernard I would be delighted to meet with you to discuss the potentials of our services as well as the opportunities of partnership and strategic alliance. Please do not hesitate to make your offers for partnering via the One-on-One system of BIO, or by contacting me directly at firstname.lastname@example.org .